Savara Inc
No enriched coverage for $SVRA in the last 7 days.
No SEC Form 4 filings for $SVRA in the last 30 days.
The FDA’s August 2026 Prescription Drug User Fee Act calendar includes target action dates for multiple investigational drugs and therapies. Moderna’s mRNA-1010 has an Aug 5, 2026 PDUFA date. Gilead’s bictegravir/lenacapavir has Aug 27. Lantheus’ MK-6240 has Aug 13. Other listed PDUFA dates cover programs from Capricor, BMS, Jazz, Savara, Ultragenyx, PharmaEssentia, Regeneron, Takeda, and Priovant.
Savara Inc. (Nasdaq: SVRA) said the European Patent Office granted a patent for the liquid formulation of MOLBREEVI, covering protection in Europe through March 2041 (EP No. 4121000). It also said Australia’s patent office granted a related patent (No. 62/990,810) through March 2041. MOLBREEVI is in Phase 3 for autoimmune PAP.
Lowrance David L (Chief Financial Officer) sold 394,528 shares of Savara Inc (SVRA) at $5.68 ($2.24M total) on 2026-06-22.
Recent SVRA coverage spans financial news, corporate actions and regulation.
The absence of an advisory committee meeting may reduce one source of review uncertainty, while the Aug 22 PDUFA date remains a key catalyst.
Granted formulation patents reduce ex-US competitive risk and strengthen the MOLBREEVI IP moat, but do not change near-term clinical/regulatory timelines.
Routine insider sale disclosed via Form 4; may slightly affect near-term sentiment but no new fundamentals are provided.
Board-approved equity plan expansion plus CFO/COO-to-CFO transition and severance/consulting terms can shift dilution expectations and near-term governance risk.
Savara's Q1 earnings report indicates a wider-than-expected loss per share, which may exert short-term downward pressure on the stock. The company's focus on rare respiratory diseases and ongoing Phase III development for molgramostim nebulizer suggests potential long-term growth if clinical results are favorable.
alphai scores every news story that mentions SVRA with an AI model for sentiment and relevance, and aggregates insider trades from Savara Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA’s August 2026 Prescription Drug User Fee Act calendar includes target action dates for multiple investigational drugs and therapies. Moderna’s mRNA-1010 has an Aug 5, 2026 PDUFA date. Gilead’s bictegravir/lenacapavir has Aug 27. Lantheus’ MK-6240 has Aug 13. Other listed PDUFA dates cover programs from Capricor, BMS, Jazz, Savara, Ultragenyx, PharmaEssentia, Regeneron, Takeda, and Priovant.
4 min readSavara Inc. (Nasdaq: SVRA) said the European Patent Office granted a patent for the liquid formulation of MOLBREEVI, covering protection in Europe through March 2041 (EP No. 4121000). It also said Australia’s patent office granted a related patent (No. 62/990,810) through March 2041. MOLBREEVI is in Phase 3 for autoimmune PAP.
3 min readLowrance David L (Chief Financial Officer) sold 394,528 shares of Savara Inc (SVRA) at $5.68 ($2.24M total) on 2026-06-22.
2 min readSavara Inc (SVRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K Savara Inc false 0001160308 --12-31 0001160308 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event rep
6 min readSavara Inc. (SVRA) reported a Q1 per-share loss of $-0.15, which is wider than the FactSet estimate of a $-0.13 loss. The clinical-stage biopharmaceutical company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP).
3 min readSavara's first-quarter net loss has widened due to increased research and development costs. The article, sourced from Reuters via Refinitiv, is a concise report on the company's financial performance for Q1.
2 min readSavara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced its management team will attend the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. They will participate in a fireside chat on May 19th at the NASDAQ headquarters. A live webcast and replay will be available on the company’s corporate website for 90 days.
3 min readJefferies has reiterated a Buy rating and $10.50 price target for Savara (NASDAQ:SVRA) due to high confidence in the regulatory approval of its Molbreevi treatment for autoimmune pulmonary alveolar proteinosis lung disease. The firm projects $500 million in U.S. peak sales and a potential EU approval by Q1 2027, with the stock currently trading at $5.05 after a 77% return over the past year. Regulatory hurdles have been addressed, and both the FDA and EMA are progressing with Molbreevi's applications without an advisory committee for the former.
4 min readH.C. Wainwright & Co. reiterated a Buy rating and US$10.00 price target for Savara Inc. (SVRA:NASDAQ), anticipating a mid-2026 launch for its drug Molbreevi. The regulatory path has been de-risked by the FDA's decision not to convene an Advisory Committee, leading to growing commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals for the rare autoimmune PAP market. Analysts project Molbreevi to generate $24.4 million in revenue in 2026, growing to $69.5 million in 2027, with profitability modeled for 2028.
3 min readSavara Inc. recently announced that the FDA granted Priority Review for its Biologics License Application for MOLBREEVI, setting a PDUFA action date of August 22, 2026. This development significantly sharpens Savara’s investment profile by creating a defined regulatory timeline and linking capital availability to MOLBREEVI's approval. While this status is material given strong share gains, it also raises the stakes, making execution missteps or an adverse FDA outcome more consequential for the company.
4 min read
